Heron Therapeutics, Inc. /De/ (HRTX) Institutional Ownership

Ownership Summary

Heron Therapeutics, Inc. /De/ (NASDAQ:HRTX) appears in 168 institutional 13F filings for the quarter ending December 2025.

• They owned 91.8% of outstanding stock in December 2025, up from 90.8% the prior quarter.
• Their total shares held in HRTX increased 6.35% quarter over quarter, and separately, investors owning Heron Therapeutics increased 6.33% from a year ago.
• During the quarter, 81 of these 168 funds increased positions in HRTX, 44 reduced exposure, and 43 held steady.
• Institutional investors collectively held 156.45Mn shares in Heron Therapeutics as of December 2025, up by 9.34Mn shares quarter on quarter, and up 36.82Mn shares year over year.
• As of December 31, 2025, Rubric Capital Management LP held the largest stake in Heron Therapeutics with 30.05Mn shares, accounting for 17.64% of total shares outstanding.
• The most significant purchases of HRTX for the quarter ending December 2025 came from MILLENNIUM MANAGEMENT LLC (6.92Mn), TANG CAPITAL MANAGEMENT LLC (2.8Mn), Clearline Capital LP (2.52Mn), VANGUARD GROUP INC (1.36Mn), JANE STREET GROUP, LLC (1.15Mn).
• Top sellers of HRTX stock for the quarter ending December 2025 included Jpmorgan Chase & Co (2.52Mn), Citigroup Inc (2.47Mn), AQR CAPITAL MANAGEMENT LLC (1.56Mn), Morgan Stanley (1.5Mn), Bank Of America Corp /De/ (1.33Mn).
• Business Quant data shows the 10 biggest positions in Heron Therapeutics as of December 2025 are held by Rubric Capital Management LP (30.05Mn), Clearline Capital LP (12.24Mn), ADAGE CAPITAL PARTNERS GP, L.L.C. (11.19Mn), BlackRock, Inc. (10.22Mn), VANGUARD GROUP INC (9.82Mn), Velan Capital Investment Management LP (8.75Mn), MILLENNIUM MANAGEMENT LLC (7.17Mn), PALISADE CAPITAL MANAGEMENT, LP (6.33Mn), TANG CAPITAL MANAGEMENT LLC (6.25Mn), Tejara Capital Ltd (5.13Mn).